M2 EQUITYBITES-May 3, 2019-Abbott wins WHO PQ approval for world-first point-of-care
viral load HIV diagnostic test
Global Banking News-May 3, 2019-Abbott wins WHO PQ approval for world-first point-of-care
viral load HIV diagnostic test
[4] Several factors like age at infection, gender, mode of infection, genotype, and
viral load have been reported as important predictors of outcome of the disease progression.
Compared with white HIV-positive gay or bisexual men in a large US study, black gay or bisexual men were less likely to take antiretroviral therapy * and less likely to have an undetectable
viral load. (1)
A 2,000 mg loading dose of ibalizumab was infused into patients after a seven-day control period in which patients continued to receive their current therapy; the
viral load was quantified seven days later.
Although antiretroviral therapy (ART) prescriptions among persons in HIV care increased overall from 89% in 2009 to 94% in 2013, fewer blacks than Hispanics or Latinos (Hispanics) and non-Hispanic whites (whites) were on ART and had a suppressed
viral load (<200 HIV RNA copies/mL) in their most recent
viral load test result (3).
Nucleic acid amplification tests (NAATs) are the current gold standard for the determination of
viral load (VL) in plasma or serum through quantitative measurement of RNA or DNA targets.
Indeed, the Diagnostic Access Initiative (http://www.unaids.org) signed in Melbourne during the 20th International AIDS Conference in July 2014, specifically focused on ensuring that all people accessing HIV treatment should have ready access to tests that monitor levels of the virus in their bodies, and underlined the importance of developing new and affordable
viral load and early infant diagnosis technology.
M2 PHARMA-October 20, 2015-FDA grants Roche approval for
viral load tests and cobas 6800/8800 Systems